VivoSeq
Oncology

Thymic Carcinoma

29

Pipeline Programs↗

6

Active Trials↗

21

Companies Involved↗

Thymic Carcinoma is an emerging landscape with 29 programs across 21 companies. The most active players are Merck & Co., Pfizer, Roche. 3 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

6/100

Mech. Concentration

13/100

Completion Rate

70/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 1Pfizer logo

Pfizer

2 programs

Phase 2Roche logo

Roche

1 program

Phase 2J

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

1 program

Phase 2G

Gynecologic Oncology Group

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

66%

Small molecule

19 of 29 classified programs — the dominant modality here.

34%ALL OTHERSMonoclonal antibody828%Protein / enzyme13%Gene therapy13%

Small molecule leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 100% of 29 pipeline programs.

Analysis

Trial Status

21

clinical trials

Completed7 · 33%
Unknown status5 · 24%
Recruiting3 · 14%
Terminated3 · 14%
Active, not recruiting2 · 10%
Not yet recruiting1 · 5%

Clinical Trials

Trial Activity

21 trials

Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma
Recruiting·FFudan University·Phase 3·NCT02633514·1 enrolled
First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
Recruiting·National Cancer Center, Japan·Phase 2·NCT05832827·35 enrolled
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06838910·20 enrolled
Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT04417660·9 enrolled
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01025089·18 enrolled
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
Not yet recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 2·NCT07324629·30 enrolled
Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma
Completed·IIndiana University School of Medicine·Phase 1·NCT00314873·11 enrolled
A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma
Completed·Roche logoRoche·Phase 2·NCT04321330·34 enrolled
Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma
Completed·PPatrick Joseph Loehrer Sr.·Phase 2·NCT00198133·27 enrolled
A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma
Completed·SSeoul National University Hospital·Phase 2·NCT02623127·25 enrolled
Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
Completed·National Cancer Institute (NCI)·Phase 2·NCT00965250·49 enrolled
Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents
Completed·MMedSIR·Phase 2·NCT04710628·43 enrolled
Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
Completed·—·Phase 2·NCT02049047·41 enrolled
KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma
Terminated·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 2·NCT04469725·95 enrolled
A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors
Terminated·WWeill Medical College of Cornell University·Phase 2·NCT04925947·4 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)